Target specificity of selective estrogen receptor modulators within human endometrial cancer cells

被引:30
|
作者
Bramlett, KS [1 ]
Burris, TP [1 ]
机构
[1] Lilly Corp Ctr, Lilly Res Labs, Gene Regulat & Bone Res, Indianapolis, IN 46285 USA
关键词
nuclear receptor; SERM; lasofoxifene; coactivator; raloxifene; ALKALINE-PHOSPHATASE ACTIVITY; CONFORMATIONAL-CHANGES; GENE-EXPRESSION; ER BETA; COACTIVATOR; BINDING; ANTIESTROGEN; AGONIST; ALPHA; PROLIFERATION;
D O I
10.1016/S0960-0760(03)00258-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Selective estrogen receptor modulators (SERMs) are estrogen receptor (ER) ligands that function as antagonists in some tissues, but have either partial or full agonist activity in others. SERMs often display variable partial agonist activity in uterine tissues and this activity can be displayed in uterine cell lines such as the human Ishikawa endometrial adenocarcinoma cell line. In this study, we compared the effects of several ER ligands including some SERMs on alkaline phosphatase (AP) activity and the expression of an ER target gene, the progesterone, receptor (PR), in Ishikawa cells. As expected, estradiol (E2) was a potent and efficacious activator of both AP activity and PR mRNA expression. 4-Hydroxytamoxifen (4OHT) stimulated AP activity to a level 47% of that of E2 (100 nM), while CP 336156 (lasofoxifene) increased AP activity 18%. A benzothiophene, such as LY 117018, a raloxifene analog, stimulated AP even less with values approximately 11% of E2-stimulated levels. A pure antiestrogen, ICI 182,780 did not stimulate AP activity. Interestingly, when we examined the ability of these compounds to increase the expression of the ER target gene, PR, a different rank order of efficacy was detected. After E2, CP 336156 was the most efficacious in increasing PR mRNA with a maximal stimulation of 20% of E2 levels, while 4OHT stimulated only 17%. LY 117018 increased PR mRNA expression 8% while ICI 182,780 did not increase PR mRNA expression at all. These data illustrate the target specificity that a SERM is able to display within a single cell type independent of "tissue specificity" and differential levels of expression of various cofactors. While 4OHT is 160% more active than CP 336156 in terms of inducing AP activity in the Ishikawa cells. CP 336156 has equivalent activity as 4OT when one examines the ability of these SERMs to induce PR mRNA expression. Since the stimulation of Ishikawa cells by ER ligands is often used to assess the potential in vivo uterotrophic activity, these data indicate that examination of several endpoints in these cells may be necessary in order to fully characterize the activity of SERMs. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:27 / 34
页数:8
相关论文
共 50 条
  • [1] Regulation of estrogen target genes and growth by selective estrogen-receptor modulators in endometrial cancer cells
    Dardes, RC
    Schafer, JM
    Pearce, ST
    Osipo, C
    Chen, B
    Jordan, VC
    GYNECOLOGIC ONCOLOGY, 2002, 85 (03) : 498 - 506
  • [2] Selective estrogen receptor modulators and estrogen receptor α and β in breast cancer cells
    Power, KA
    Thompson, L
    FASEB JOURNAL, 2002, 16 (05): : A1003 - A1003
  • [3] A review of selective estrogen receptor modulators in the treatment of breast and endometrial cancer
    Chan, S
    SEMINARS IN ONCOLOGY, 2002, 29 (03) : 129 - 133
  • [4] Selective estrogen receptor modulators: tissue specificity and clinical utility
    Martinkovich, Stephen
    Shah, Darshan
    Planey, Sonia Lobo
    Arnott, John A.
    CLINICAL INTERVENTIONS IN AGING, 2014, 9 : 1437 - 1452
  • [5] Selective estrogen receptor modulator regulated proteins in endometrial cancer cells
    Shah, YM
    Basrur, V
    Rowan, BG
    MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2004, 219 (1-2) : 127 - 139
  • [6] Endometrial safety: a key hurdle for selective estrogen receptor modulators in development
    Pinkerton, JoAnn V.
    Goldstein, Steven R.
    MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY, 2010, 17 (03): : 642 - 653
  • [7] Monocyte-macrophage system as a target for estrogen and selective estrogen receptor modulators
    Harkonen, Pirkko L.
    Vaananen, H. Kalervo
    ESTROGENS AND HUMAN DISEASES, 2006, 1089 : 218 - 227
  • [8] Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment
    Patel, Hitisha K.
    Bihani, Teeru
    PHARMACOLOGY & THERAPEUTICS, 2018, 186 : 1 - 24
  • [9] Selective estrogen receptor modulators for the chemoprevention of prostate cancer
    Steiner, MS
    Raghow, S
    Neubauer, BL
    UROLOGY, 2001, 57 (4A) : 68 - 72
  • [10] The selective estrogen receptor modulators in breast cancer prevention
    Fangxuan Li
    Jinli Dou
    Lijuan Wei
    Shixia Li
    Juntian Liu
    Cancer Chemotherapy and Pharmacology, 2016, 77 : 895 - 903